Evidence map›Paper›PMID 31754347›Full record

ArticleCancer cell international2019

Two predictive precision medicine tools for hepatocellular carcinoma.

Zhiqiao Zhang, Jing Li, Tingshan He, Yanling Ouyang, Yiyan Huang, Qingbo Liu, Peng Wang, Jianqiang Ding

Abstract read
In one paragraph

Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhiqiao Zhang *1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.ORCID 0000-0003-4631-8818
Jing Li *1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Tingshan He *1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Yanling Ouyang1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Yiyan Huang1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Qingbo Liu2Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Peng Wang1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.
Jianqiang Ding1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a serious threat to public health due to its poor prognosis. The current study aimed to develop and validate a prognostic nomogram to predict the overall survival of HCC patients.

methodsThe model cohort consisted of 24,991 mRNA expression data points from 348 HCC patients. The least absolute shrinkage and selection operator method (LASSO) Cox regression model was used to evaluate the prognostic mRNA biomarkers for the overall survival of HCC patients.

resultsUsing multivariate Cox proportional regression analyses, a prognostic nomogram (named Eight-mRNA prognostic nomogram) was constructed based on the expression data of N4BP3, -ADRA2B, E2F8, MAPT, PZP, HOXD9, COL15A1, and -NDST3. The C-index of the Eight-mRNA prognostic nomogram was 0.765 (95% CI 0.724-0.806) for the overall survival in the model cohort. The Harrell's concordance-index of the Eight-mRNA prognostic nomogram was 0.715 (95% CI 0.658-0.772) in the validation cohort. The survival curves demonstrated that the HCC patients in the high risk group had a significantly poorer overall survival than the patients in the low risk group.

conclusionIn the current study, we have developed two convenient and efficient predictive precision medicine tools for hepatocellular carcinoma. These two predictive precision medicine tools are helpful for predicting the individual mortality risk probability and improving the personalized comprehensive treatments for HCC patients. The Smart Cancer Predictive System can be used by clicking the following URL: https://zhangzhiqiao2.shinyapps.io/Smart_cancer_predictive_system_HCC_2/. The Gene Survival Analysis Screen System is available at the following URL: https://zhangzhiqiao5.shinyapps.io/Gene_Survival_Analysis_A1001/.

Indexed as

Hepatocellular carcinomamRNANomogramOverall survivalPrognosis

Identifiers

PMID31754347
PMCPMC6854692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.